MISSISSAUGA, ON, April 26, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that experienced healthcare executive Dr. Laurence Terrisse-Rulleau is being proposed for election to Cipher's Board of Directors at the Company's Annual and Special Meeting on May 10, 2018.
Dr. Rulleau is currently a partner at CTI Life Sciences, a biotech venture capital firm that makes investments in high quality emerging life sciences companies at the pre-clinical, clinical and revenues stage in Canada and the U.S. In her capacity as a partner, she is serving on Boards of Directors of both private and public companies in North America. Prior to this role, Dr. Rulleau served as Vice-President Business Development of Univalor, the technology transfer office of the Université de Montréal, from November 2011 to November 2014. Under her leadership at Univalor, more than 40 licenses with industry partners were signed and eight companies were formed. Prior to joining Univalor, Dr. Rulleau served as Chief Executive Officer of HLA-G Technologies, a biotechnology start-up based in France. Dr. Rulleau also has over 10 years of experience as a health sciences analyst at a several Canadian investment banks where she was involved in numerous transactions such as mergers and acquisitions, IPOs and financings. Dr. Rulleau has a Masters in Biology from The Universite du Quebec and a Ph.D. from Montreal University executed at the Montreal Clinical Research Institute
"We're pleased to attract such a highly accomplished and recognized healthcare executive to the Cipher Board," said Mark Beaudet, Chair of Cipher's Board of Directors. "Laurence brings extensive transaction and industry experience that complements and strengthens Cipher's Board of Directors."
Dr. Rulleau commented: "I have known Cipher since its initial public listing, and I'm excited to join the Board at this important stage in the Company's evolution. Leveraging my background and relationships, I look forward to assisting the team as it continues to execute on the strategy to build a diversified portfolio of products across multiple therapeutic categories."
About Cipher Pharmaceuticals Inc.
Cipher (TSX:CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. Cipher is focused on a three-pronged growth strategy – including acquisitions, in-licensing, and selective investments in drug development – to assemble a broad portfolio of prescription products that serve unmet medical needs. For more information, visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.
For further information: Craig Armitage, LodeRock Advisors, (416) 347-8954, [email protected]